alexa A Role for Intralesional (Intratumoral) Therapy with Two Cytokines in the Management of Some High Risk Patients with Cutaneous Melanoma | OMICS International
ISSN: 2161-1076
Surgery: Current Research

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

A Role for Intralesional (Intratumoral) Therapy with Two Cytokines in the Management of Some High Risk Patients with Cutaneous Melanoma

E George Elias*1 and Bhuvnesh K Sharma2

1University of Maryland St. Joseph Medical Center, Towson, Maryland, USA

2ScyTek Laboratories, Logan, Utah, USA

*Corresponding Author:
Elias EG
MD, Phd University of Maryland St. Joseph Medical Center
Towson, Maryland, USA
Tel: 1-410-337-1000
E-mail: [email protected]

Received date: 22 December 2014; Accepted date: 23 March 2015; Published date: 31 March 2015

Citation: E George Elias Bhuvnesh K Sharma (2015) A Role for Intralesional (Intratumoral) Therapy with Two Cytokines in the Management of Some High Risk Patients with Cutaneous Melanomay. Surgery Curr Res 5:226. doi:10.4172/2161-1076.1000226

Copyright: © 2015 Elias EG et al, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Surgery: Current Research

Commentary

Despite of all preventive measures, the incidence of cutaneous melanoma continues to rise. While surgery can induce potential cure in patients with low risk primary disease, adjuvant therapy is needed in addition to surgery in high risk patients with primary melanoma. High risk patients include those with invasive primary of 0.75 mm depth of invasion, the presence of ulceration or mitosis at the primary site regardless to the depth of invasion. The objective of adjuvant therapy is to prevent disease recurrence and metastases and improve patients’ survival. Several approaches and a variety of agents were administered systemically in the postoperative period, i.e., post resection of the primary site, with and without regional lymphadenectomy, and some resulted in limited success but far from having major impact on the disease. In the meantime, sentinel lymph node identification and excisional biopsy identified occult metastases that can be surgically eliminated, but more importantly is to initiate adjuvant therapy in relatively early stage of the disease. Again, this failed to show survival advantage.

Furthermore, patients with in-transit metastases, without any evidence of other metastases, have very guarded prognosis. Repeated local excisions, even with hyperthermic limb perfusion, and intralesional therapy with various drugs revealed very limited response rates without any survival benefits.

While melanoma is an immunogenic tumor, it seems to be very heterogeneous as it expresses various melanoma-specific antigens, peptides and has variable genetic profiles among different patients. Therefore, autoimmunization may overcome such heterogeneity.

In the meantime, it has been shown that intralesional administration of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in multiple small in-transit metastases at doses ranging from 400-500 microgram (μg) daily for 4-5 consecutive days and repeated every 21-28 days, gave high response rate but with some side effects such as leukocytosis and fatigue. In addition, intralesional administration of interleukin-2 (IL-2) at doses ranging from 0.6-18 million IU, 2-3 times per week, resulted in over 60% response rate but with 58% systemic side effects at the higher dosages.

On the other hand, to avoid the side effects and the development of immune tolerance, when GM-CSF was administered at low nontoxic dose of 500 μg once per week, it resulted in high response rate in small in-transit metastases that ranged in size from few mm up to 1 cm located in the skin and subcutaneous tissue. Of 127 lesions treated, 110 had complete response to GM-CSF therapy, and the other 17 lesions failed but were successfully treated with low dose IL-2 of 11 million IU weekly. There were no systemic side effects but only local skin reaction at the injection sites. Furthermore, preoperative sequential administration of 500 μg once at the primary site of invasive cutaneous melanoma followed the next day by IL-2 administration once, at the same site, of 11 million IU, one week before the definitive standard surgical procedure. The resected tissues showed complete tumor necrosis with massive histiocytosis. In addition, immunohistochemical studies on the resected tissue revealed overexpression of helper (CD4+) and cytotoxic T cells (CD8+) at the injection sites and in some regional lymph nodes. This clearly indicated a massive immune response at the injection sites that seemed to be transmitted via the lymphatics. The first treated patient had stage IIIC disease and is alive, free of disease, for over 4½ years.

It has been shown that intralesional administration of GM-CSF can activate and increase the number of dendritic cells at the injection site as well as at the regional lymph nodes, while intralesional administration of IL-2 can activate Tumor Infiltrating Lymphocyte (TIL). The function of these 2 cytokines can complement one another. Dendritic cells are very efficient Antigen Presenting Cells (APCs) that are capable of processing the tumor antigens and subsequently present the processed antigens to T lymphocytes, activated by IL-2 administration, creating tumor-specific cytotoxic T cells in vivo. This approach utilizes patient own tumor (before excision) as the source for tumor-specific antigens to any given patient. It also seems to improve patients’ survival.

However, this approach is not effective in large size tumors of 2 cm or more. In addition, it should not be used in the presence of an infected melanoma lesion as it can result in immune deviation by recognizing the bacterial antigens rather than the tumor. Autoimmunization utilizing sequential intralesional administration of GM-CSF followed by IL-2 seems to be very effective approach that can overcome melanoma heterogeneity. It lends itself to be evaluated as adjuvant therapy in controlled clinical trials.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 11920
  • [From(publication date):
    May-2015 - Jun 21, 2018]
  • Breakdown by view type
  • HTML page views : 8130
  • PDF downloads : 3790
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]e.com

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7